T. Rowe Price Associates
IBRX icon

T. Rowe Price Associates’s ImmunityBio IBRX Stock Holding History

T. Rowe Price Associates’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.26M Buy
294,831
+136,589
+86% +$935K ﹤0.01% 1775
2025
Q4 		$314K Buy
158,242
+37,188
+31% +$84.3K ﹤0.01% 2622
2025
Q3 		$298K Buy
121,054
+6,057
+5% +$15.6K ﹤0.01% 2606
2025
Q2 		$304K Buy
114,997
+48,896
+74% +$131K ﹤0.01% 2519
2025
Q1 		$199K Buy
66,101
+9,813
+17% +$29.7K ﹤0.01% 2640
2024
Q4 		$145K Sell
56,288
-18,959
-25% -$79K ﹤0.01% 2774
2024
Q3 		$281K Sell
75,247
-55,514
-42% -$257K ﹤0.01% 2505
2024
Q2 		$828K Buy
130,761
+6,882
+6% +$45.4K ﹤0.01% 1975
2024
Q1 		$667K Buy
123,879
+4,533
+4% +$20.5K ﹤0.01% 2089
2023
Q4 		$601K Buy
119,346
+8,834
+8% +$27.7K ﹤0.01% 2099
2023
Q3 		$187K Sell
110,512
-32,028
-22% -$64.3K ﹤0.01% 2524
2023
Q2 		$398K Sell
142,540
-24,218
-15% -$68.5K ﹤0.01% 2238
2023
Q1 		$304K Buy
166,758
+16,800
+11% +$52.2K ﹤0.01% 2338
2022
Q4 		$760K Sell
149,958
-7,908
-5% -$43.4K ﹤0.01% 1924
2022
Q3 		$785K Buy
157,866
+11,149
+8% +$50.8K ﹤0.01% 1882
2022
Q2 		$546K Sell
146,717
-18,404
-11% -$73.9K ﹤0.01% 2190
2022
Q1 		$926K Sell
165,121
-26,281
-14% -$161K ﹤0.01% 2047
2021
Q4 		$1.16M Buy
191,402
+9,300
+5% +$69.9K ﹤0.01% 1949
2021
Q3 		$1.77M Sell
182,102
-32,906
-15% -$362K ﹤0.01% 1783
2021
Q2 		$3.07M Buy
215,008
+12,070
+6% +$199K ﹤0.01% 1608
2021
Q1 		$4.82M Buy
+202,938
New +$5.26M ﹤0.01% 1475

Other funds holding IBRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

T. Rowe Price Associates's IBRX Position: Q1 2026 in Review

T. Rowe Price Associates increased its ImmunityBio (IBRX) stake by 86% in Q1 2026, buying an estimated $935K and bringing the position to 294,831 shares worth $2.26M. The position accounts for ﹤0.01% of the portfolio, ranked #1775.

T. Rowe Price Associates first reported a position in IBRX in Q1 2021 and has held it in 21 quarters since. The position peaked at $4.82M in Q1 2021. 386 funds tracked by Wall St. Rank hold IBRX as of Q1 2026.

  • T. Rowe Price Associates held 294,831 shares of ImmunityBio worth $2.26M as of Q1 2026.
  • T. Rowe Price Associates bought 136,589 ImmunityBio shares in Q1 2026, an estimated $935K.
  • ImmunityBio made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #1775 holding.
  • T. Rowe Price Associates first reported a position in ImmunityBio in Q1 2021 and has held it in 21 quarters since.
  • T. Rowe Price Associates's ImmunityBio position peaked at $4.82M in Q1 2021.
  • 386 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.